PF-07338018

PF-07338018 is an investigational 20-valent pneumococcal conjugate vaccine (20vPnC) developed by Pfizer for the prevention of invasive disease and pneumonia caused by *Streptococcus pneumoniae*. It contains capsular polysaccharide antigens from 20 different pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F), each individually conjugated to a CRM197 carrier protein. This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, enhancing the immune response and inducing immunological memory, which is particularly critical for protection in infants and young children. While Pfizer markets a 20-valent vaccine under the brand name Prevenar 20 (PF-06482077), PF-07338018 is a specific investigational formulation utilized in clinical trials for pediatric populations and as a core component of next-generation, expanded multivalent vaccine regimens (such as 25-valent or 26-valent candidates). It is currently being evaluated in Phase 3 trials to assess its safety, tolerability, and immunogenicity in healthy infants.

Other names

20-valent pneumococcal conjugate vaccine20vPnCPCV20PCV-20PCV 20